Kv7 potassium channels in airway smooth muscle cells:signal transduction intermediates and pharmacological targets for bronchodilator therapy

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 302, Issue 1, 2012, Pages

  Brueggemann, Lioubov I ^a   Kakad, Priyanka P ^a   Love, Robert B ^b   Solway, Julian ^c   Dowell, Maria L ^c   Cribbs, Leanne L ^a   Byron, Kenneth L ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

Asthma therapy; Bronchoconstrictor signal transduction; Kcnq voltage activated potassium channel; Precision cut lung slice

Indexed keywords

10,10 BIS(4 PYRIDINYLMETHYL) 9(10H) ANTHRACENONE; 2,5 DIMETHYLCELECOXIB; BRONCHODILATING AGENT; CELECOXIB; FLUPIRTINE; HISTAMINE; METHACHOLINE; POTASSIUM CHANNEL; POTASSIUM CHANNEL KCNQ; POTASSIUM CHANNEL KV7; RETIGABINE; UNCLASSIFIED DRUG; VERAPAMIL;

AIRWAY CONSTRICTION; AMPLITUDE MODULATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREATHING MUSCLE; DRUG TARGETING; ELECTROPHYSIOLOGY; GUINEA PIG; HUMAN; HUMAN CELL; LUNG SLICE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER;

AMINOPYRIDINES; ANIMALS; ANTHRACENES; BRONCHOCONSTRICTION; BRONCHODILATOR AGENTS; CALCIUM CHANNEL BLOCKERS; CARBAMATES; GUINEA PIGS; HISTAMINE; HUMANS; KCNQ POTASSIUM CHANNELS; MALE; METHACHOLINE CHLORIDE; MYOCYTES, SMOOTH MUSCLE; PATCH-CLAMP TECHNIQUES; PHENYLENEDIAMINES; PYRAZOLES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SULFONAMIDES; VERAPAMIL;

EID: 83755196214     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00194.2011     Document Type: Article

References (46)

1. Barnes PJ. Clinical studies with calcium antagonists in asthma. Br J Clin Pharmacol 20: 289S-298S, 1985.
2. Belmonte KE. Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc Am Thorac Soc 2: 297-304, 2005.
3. Brannan JD. Bronchial hyperresponsiveness in the assessment of asthma control. Chest 138: 11S-17S, 2010.
4. Brueggemann LI, Mackie AR, Mani BK, Cribbs LL, Byron KL. Differential effects of selective cyclooxygenase-2 inhibitors on vascular smooth muscle ion channels may account for differences in cardiovascular risk profiles. Mol Pharmacol 76: 1053-1061, 2009.
5. Brueggemann LI, Mackie AR, Martin JL, Cribbs LL, Byron KL. Diclofenac distinguishes among homomeric and heteromeric potassium channels composed of KCNQ4 and KCNQ5 subunits. Mol Pharmacol 79: 10-23, 2011.
6. Brueggemann LI, Moran CJ, Barakat JA, Yeh JZ, Cribbs LL, Byron KL. Vasopressin stimulates action potential firing by protein kinase C-dependent inhibition of KCNQ5 in A7r5 rat aortic smooth muscle cells. Am J Physiol Heart Circ Physiol 292: H1352-H1363, 2007.
7. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159, 1987.
8. Cockcroft DW. Direct challenge tests. Airway hyperresponsiveness in asthma: its measurement and clinical significance. Chest 138: 18S-24S, 2010.
9. Daham K, Song WL, Lawson JA, Kupczyk M, Gülich A, Dahlén SE, FitzGerald GA, Dahlén B. Effects of celecoxib on major prostaglandins in asthma. Clin Exp Allergy 41: 36-45.
10. Delmas P, Brown DA. Pathways modulating neural KCNQ/M (Kv7) potassium channels. Nat Rev Neurosci 6: 850-862, 2005.
11. Fish JE. Calcium channel antagonists in the treatment of asthma. J Asthma 21: 407-418, 1984.
12. Frolov RV, Berim IG, Singh S. inhibition of delayed rectifier potassium channels and induction of arrhythmia: a novel effect of celecoxib and the mechanism underlying it. J Biol Chem 283: 1518-1524, 2008.
13. Hamid Q, Tulic M. Immunobiology of asthma. Annu Rev Physiol 71: 489-507, 2009.
14. Hirota S, Helli P, Janssen LJ. Ionic mechanisms and Ca2_ handling in airway smooth muscle. Eur Respir J 30: 114-133, 2007.
15. Janssen LJ. Ionic mechanisms and Ca2_ regulation in airway smooth muscle contraction: do the data contradict dogma? Am J Physiol Lung Cell Mol Physiol 282: L1161-L1178, 2002.
16. Janssen LJ, Sims SM. Acetylcholine activates non-selective cation and chloride conductances in canine and guinea-pig tracheal myocytes. J Physiol 453: 197-218, 1992.
17. Jentsch TJ. Neuronal KCNQ potassium channels: physiology and role in disease. Nat Rev Neurosci 1: 21-30, 2000.
18. Jepps TA, Greenwood IA, Moffatt JD, Sanders KM, Ohya S. Molecular and functional characterization of Kv7 K_ channel in murine gastrointestinal smooth muscles. Am J Physiol Gastrointest Liver Physiol 297: G107-G115, 2009.
19. Joshi S, Balan P, Gurney AM. Pulmonary vasoconstrictor action of KCNQ potassium channel blockers. Respir Res 7: 31, 2006.
20. Joshi S, Sedivy V, Hodyc D, Herget J, Gurney AM. KCNQ modulators reveal a key role for KCNQ potassium channels in regulating the tone of rat pulmonary artery smooth muscle. J Pharmacol Exp Ther 329: 368-376, 2009.
21. Jude JA, Wylam ME, Walseth TF, Kannan MS. Calcium signaling in airway smooth muscle. Proc Am Thorac Soc 5: 15-22, 2008.
22. Kajita J, Yamaguchi H. Calcium mobilization by muscarinic cholinergic stimulation in bovine single airway smooth muscle. Am J Physiol Lung Cell Mol Physiol 264: L496-L503, 1993.
23. Kardosh A, Wang W, Uddin J, Petasis NA, Hofman FM, Chen TC, Schonthal AH. Dimethyl-celecoxib (DMC), a derivative of celecoxib that lacks cyclooxygenase-2-inhibitory function, potently mimics the antitumor effects of celecoxib on Burkitt's lymphoma in vitro and in vivo. Cancer Biol Ther 4: 571-582, 2005.
24. Kowalski ML, Makowska J. Use of nonsteroidal anti-inflammatory drugs in patients with aspirin hypersensitivity: safety of cyclo-oxygenase-2 inhibitors. Treat Respir Med 5: 399-406, 2006.
25. Levitan IB. Signaling protein complexes associated with neuronal ion channels. Nat Neurosci 9: 305-310, 2006.
26. Liang GH, Jin Z, Ulfendahl M, Jarlebark L. Molecular analyses of KCNQ1-5 potassium channel mRNAs in rat and guinea pig inner ears: expression, cloning, and alternative splicing. Acta Otolaryngol (Stockh) 126: 346-352, 2006.
27. Macías Á, Moreno C, Moral-Sanz J, Cogolludo Á, David M, Alemanni M, Pérez-Vizcaíno F, Zaza A, Valenzuela C, González T. Celecoxib blocks cardiac Kv1.5, Kv43 and Kv71 (KCNQ1) channels: effects on cardiac action potentials. J Mol Cell Cardiol 49: 984-992, 2010.
28. Mackie AR, Brueggemann LI, Henderson KK, Shiels AJ, Cribbs LL, Scrogin KE, Byron KL. Vascular KCNQ potassium channels as novel targets for the control of mesenteric artery constriction by vasopressin, based on studies in single cells, pressurized arteries, and in vivo measurements of mesenteric vascular resistance. J Pharmacol Exp Ther 325: 475-483, 2008.
29. Mackie AR, Byron KL. Cardiovascular KCNQ (Kv7) potassium channels: physiological regulators and new targets for therapeutic intervention. Mol Pharmacology 74: 1171-1179, 2008.
30. Malerba M, Radaeli A, Mancuso S, Polosa R. The potential therapeutic role of potassium channel modulators in asthma and chronic obstructive pulmonary disease. J Biol Reg Homeost Agents 24: 123-130, 2010.
31. Mani BK, Brueggemann LI, Cribbs LL, Byron KL. Activation of vascular KCNQ (Kv7) potassium channels reverses spasmogen-induced constrictor responses in rat basilar artery. Br J Pharmacol 164: 237-249, 2011.
32. McCallum LA, Pierce SL, England SK, Greenwood IA, Tribe RM. The contribution of Kv7 channels to pregnant mouse and human myometrial contractility. J Cell Mol Med 15: 577-586, 2011.
33. Mitchell HW. Electromechanical effects of tetraethylammonium and K_ on histamine-induced contraction in pig isolated tracheal smooth muscle. Lung 165: 129-142, 1987.
34. Navarro-Lopez J, Jimenez-Diaz L, Geranton SM, Ashmore JF. Electrophysiological and molecular analysis of Kv7/KCNQ potassium channels in the inferior colliculus of adult guinea pig. J Mol Neurosci 37: 263-268, 2009.
35. Ng FL, Davis AJ, Jepps TA, Harhun MI, Yeung SY, Wan A, Reddy M, Melville D, Nardi A, Khong TK, Greenwood IA. Expression and function of the K_ channel KCNQ genes in human arteries. Br J Pharmacol 162: 42-53, 2011.
36. Ohya S, Asakura K, Muraki K, Watanabe M, Imaizumi Y. Molecular and functional characterization of ERG, KCNQ, and KCNE subtypes in rat stomach smooth muscle. Am J Physiol Gastrointest Liver Physiol 282: G277-G287, 2002.
37. Penn RB. Embracing emerging paradigms of G protein-coupled receptor agonism and signaling to address airway smooth muscle pathobiology in asthma. Naunyn Schmiedebergs Arch Pharmacol 378: 149-169, 2008.
38. Penn RB, Benovic JL. Regulation of heterotrimeric G protein signaling in airway smooth muscle. Proc Am Thorac Soc 5: 47-57, 2008.
39. Perez-Zoghbi JF, Karner C, Ito S, Shepherd M, Alrashdan Y, Sanderson MJ. Ion channel regulation of intracellular calcium and airway smooth muscle function. Pulm Pharmacol Ther 22: 388-397, 2009.
40. Rossetti M, Savineau JP, Crevel H, Marthan R. Role of protein kinase C in nonsensitized and passively sensitized human isolated bronchial smooth muscle. Am J Physiol Lung Cell Mol Physiol 268: L966-L971, 1995.
41. Schönthal AH, Chen TC, Hofman FM, Louie SG, Petasis NA. Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs. Expert Opin Investig Drugs 17: 197-208, 2008.
42. Smith N, Johnson FJ. Early-and late-phase bronchoconstriction, airway hyper-reactivity and cell influx into the lungs, after 5'-adenosine monophosphate inhalation: comparison with ovalbumin. Clin Exp Allergy 35: 522-530, 2005.
43. West PM, Fernandez C. Safety of COX-2 inhibitors in asthma patients with aspirin hypersensitivity. Ann Pharmacother 37: 1497-1501, 2003.
44. Wickenden AD, Zou A, Wagoner PK, Jegla T. Characterization of KCNQ5/Q3 potassium channels expressed in mammalian cells. Br J Pharmacol 132: 381-384, 2001.
45. Yeung SY, Pucovsky V, Moffatt JD, Saldanha L, Schwake M, Ohya S, Greenwood IA. Molecular expression and pharmacological identification of a role for K(v)7 channels in murine vascular reactivity. Br J Pharmacol 151: 758-770, 2007.
46. Zhong XZ, Harhun MI, Olesen SP, Ohya S, Moffatt JD, Cole WC, Greenwood IA. Participation of KCNQ (Kv7) potassium channels in myogenic control of cerebral arterial diameter. J Physiol 588: 3277-3293, 2010.